Citadel Advisors’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.34M | Sell |
305,578
-398,996
| -57% | -$2.73M | ﹤0.01% | 5752 |
|
|
2025
Q4 | $1.4M | Sell |
704,574
-426,174
| -38% | -$966K | ﹤0.01% | 6667 |
|
|
2025
Q3 | $2.78M | Buy |
1,130,748
+344,523
| +44% | +$887K | ﹤0.01% | 5438 |
|
|
2025
Q2 | $2.08M | Buy |
786,225
+307,902
| +64% | +$828K | ﹤0.01% | 5643 |
|
|
2025
Q1 | $1.44M | Buy |
478,323
+406,572
| +567% | +$1.23M | ﹤0.01% | 6171 |
|
|
2024
Q4 | $184K | Sell |
71,751
-244,359
| -77% | -$1.02M | ﹤0.01% | 10584 |
|
|
2024
Q3 | $1.18M | Buy |
316,110
+99,132
| +46% | +$459K | ﹤0.01% | 6538 |
|
|
2024
Q2 | $1.37M | Buy |
216,978
+216,930
| +451,938% | +$1.43M | ﹤0.01% | 6016 |
|
|
2024
Q1 | $258 | Buy |
+48
| New | +$217 | ﹤0.01% | 14379 |
|
|
2023
Q2 | – | Sell |
-244,721
| Closed | -$692K | – | 14740 |
|
|
2023
Q1 | $445K | Buy |
244,721
+91,701
| +60% | +$285K | ﹤0.01% | 8544 |
|
|
2022
Q4 | $776K | Sell |
153,020
-395,134
| -72% | -$2.17M | ﹤0.01% | 7322 |
|
|
2022
Q3 | $2.72M | Sell |
548,154
-229,827
| -30% | -$1.05M | ﹤0.01% | 4998 |
|
|
2022
Q2 | $2.89M | Buy |
777,981
+438,120
| +129% | +$1.76M | ﹤0.01% | 4819 |
|
|
2022
Q1 | $1.91M | Buy |
339,861
+309,722
| +1,028% | +$1.9M | ﹤0.01% | 6193 |
|
|
2021
Q4 | $183K | Sell |
30,139
-134,746
| -82% | -$1.01M | ﹤0.01% | 11980 |
|
|
2021
Q3 | $1.61M | Buy |
164,885
+128,380
| +352% | +$1.41M | ﹤0.01% | 6919 |
|
|
2021
Q2 | $521K | Buy |
36,505
+25,969
| +246% | +$429K | ﹤0.01% | 9979 |
|
|
2021
Q1 | $250K | Buy |
+10,536
| New | +$273K | ﹤0.01% | 11231 |
|
|
2020
Q4 | – | Sell |
-306,067
| Closed | -$2.94M | – | 11183 |
|
|
2020
Q3 | $2.12M | Sell |
306,067
-204,731
| -40% | -$2.04M | ﹤0.01% | 4609 |
|
|
2020
Q2 | $6.27M | Buy |
+510,798
| New | +$2.88M | ﹤0.01% | 2769 |
|
|
2019
Q4 | – | Sell |
-14,950
| Closed | -$25.4K | – | 9382 |
|
|
2019
Q3 | $18K | Sell |
14,950
-31,554
| -68% | -$39.1K | ﹤0.01% | 8958 |
|
|
2019
Q2 | $47K | Buy |
46,504
+13,833
| +42% | +$16K | ﹤0.01% | 8744 |
|
|
2019
Q1 | $52K | Buy |
32,671
+5,618
| +21% | +$7.05K | ﹤0.01% | 8802 |
|
|
2018
Q4 | $31K | Sell |
27,053
-1,402
| -5% | -$3.21K | ﹤0.01% | 8609 |
|
|
2018
Q3 | $105K | Buy |
28,455
+13,792
| +94% | +$43.6K | ﹤0.01% | 8557 |
|
|
2018
Q2 | $45K | Sell |
14,663
-9,491
| -39% | -$35.1K | ﹤0.01% | 8459 |
|
|
2018
Q1 | $94K | Buy |
+24,154
| New | +$106K | ﹤0.01% | 7736 |
|
|
2017
Q1 | – | Sell |
-18,477
| Closed | -$106K | – | 7707 |
|
|
2016
Q4 | $106K | Buy |
+18,477
| New | +$123K | ﹤0.01% | 6653 |
|
|
2016
Q1 | – | Sell |
-14,722
| Closed | -$255K | – | 7296 |
|
|
2015
Q4 | $255K | Sell |
14,722
-115,682
| -89% | -$1.72M | ﹤0.01% | 5462 |
|
|
2015
Q3 | $1.49M | Buy |
+130,404
| New | +$2.85M | ﹤0.01% | 3303 |
|
Other funds holding IBRX
VPM
VCM
HF
WP
Citadel Advisors's IBRX Position: Q1 2026 in Review
Citadel Advisors reduced its ImmunityBio (IBRX) stake by 57% in Q1 2026, selling an estimated $2.73M and leaving 305,578 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #5752.
Citadel Advisors first reported a position in IBRX in Q3 2015 and has held it in 30 quarters since. The position peaked at $6.27M in Q2 2020. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.
- Citadel Advisors held 305,578 shares of ImmunityBio worth $2.34M as of Q1 2026.
- Citadel Advisors sold 398,996 ImmunityBio shares in Q1 2026, an estimated $2.73M.
- ImmunityBio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5752 holding.
- Citadel Advisors first reported a position in ImmunityBio in Q3 2015 and has held it in 30 quarters since.
- Citadel Advisors's ImmunityBio position peaked at $6.27M in Q2 2020.
- 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.